Health Press Release – Newsletter for December 7, 2010

Steve Newman Appointed Chief Technical Officer for Menicon Co.

Newman Taking on Worldwide Responsibility for Product Planning, Manufacturing and Technology

NAGOYA, Japan, December 7, 2010 – Menicon Co., Ltd. has announced the appointment of Steven Newman as Chief
Technical Officer for the company.
(Photo: www.newscom.com/cgi-bin/prnh/20101206/MM11663)
Newman joined Menicon with the acquisition of ClearLab's Flat Pack
technology from 1-800 Contacts in …. Read the original article  : Steve Newman Appointed Chief Technical Officer for Menicon Co..

Bill & Melinda Gates Foundation Statement on the Launch of New Meningitis Group A Vaccine

OUAGADOUGOU, Burkina Faso, December 6, 2010 – Tachi Yamada, president of the Bill & Melinda Gates Foundation's Global
Health Program, issued the following statement to mark the launch of
MenAfriVac-a new vaccine against Meningitis Group A-in Burkina Faso:

"MenAfriVac is a tremendous success story for the global health
community. It is the first vaccine … Read this article on Gaea Times at : Bill & Melinda Gates Foundation Statement on the Launch of New Meningitis Group A Vaccine.

Optical Express Announces December HD TV Give-away

Win a 46" Samsung Full HD LED TV This Christmas
GLASGOW, Scotland, December 6, 2010 – Each week during December, to celebrate superior vision, everyone who
attends a FREE laser eye surgery consultation at Optical Express will be
automatically entered into a draw to win one of four fantastic 46" Samsung
Full HD LED TVs.

… Read the original article on Gaea Times at : Optical Express Announces December HD TV Give-away.

Follow-Up Results from Study Comparing SPRYCEL(R) (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data[1]

18-Month Data Presented at 52nd Annual Meeting of the American Society of Hematology[1]

PRINCETON, New Jersey and TOKYO, December 6, 2010 – Bristol-Myers Squibb Company (www.bms.com) (NYSE:BMY) and Otsuka
Pharmaceutical Co., Ltd. today announced 18-month follow-up results from the
Phase 3 DASISION study of SPRYCEL(R) (dasatinib) 100 mg once daily vs.
imatinib (400 mg daily) in the first-line …. Read the original article  : here.

Setting the Record Straight on Hot Flushes – as Women Lift Lid on the Menopause

OXFORD, England, December 6, 2010 – A ground-breaking website today lifts the lid on the menopause – and
could save women from suffering alone, misunderstood by unsympathetic
partners and sniggering workmates.

The new section of award-winning www.healthtalkonline.org features
46 women from all walks of life – who reveal "everything you wanted to know
but were …. Original article  : Setting the Record Straight on Hot Flushes – as Women Lift Lid on the Menopause.

Cinryze(R) (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)

DUBAI, United Arab Emirates, December 6, 2010 – ViroPharma Incorporated (Nasdaq: VPHM) today announced data in five
poster presentations relating to Cinryze(R) (C1 esterase inhibitor [human])
at the 2010 International Scientific Conference of the World Allergy
Organization (WAO), December 5 through 8 in Dubai, UAE.

This is the first international presentation of these data, …. Source article on Gaea Times at  : Cinryze(R) (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO).

ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program

EXTON, Pennsylvania and WEYBRIDGE, England, December 6, 2010 – ViroPharma Incorporated (Nasdaq: VPHM) and Idis, the global leader in
developing long-term strategic solutions to therapeutic access, today
announced that the two companies have partnered to facilitate access to
certain ViroPharma products through a named patient program (NPP).
ViroPharma's NPP, developed and managed by Idis, will allow international
healthcare professionals … Read : ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program.

CIC Chooses MGS as Exclusive Reseller to Achieve eSignature Growth Objective in the Middle East

REDWOOD SHORES, California, December 6, 2010 – (OTC Bulletin Board: CICI) Communication Intelligence Corporation ("CIC")
the leading supplier of electronic signature solutions for business process
automation in the financial industry and the recognized leader in biometric
signature verification announced today the appointment of MGS, certified
reseller partner of OpenText (www.opentext.com/2/global.htm) and a
leading provider of IT consulting and implementation … Read more >>>.

Experts Reach Agreement on the Most Important Attributes of Combination Therapies for Asthma

The Agreement Will Provide Physicians With Much Needed Guidance for Choosing the Best Combination Therapy for Their Asthma Patients

CAMBRIDGE, England, December 6, 2010 – Data presented today at the World Allergy
Organization (WAO) International Conference have shown that: clinical
efficacy, safety, tolerability and speed of onset of a long-acting
Beta2-agonist (LABA), potency of an inhaled corticosteroid (ICS), …. Source article  : Experts Reach Agreement on the Most Important Attributes of Combination Therapies for Asthma.

VELCADE(R) (bortezomib) Administered Subcutaneously Shows Comparable Response Rates and Safety Profile Compared to Intravenous Administration in the Treatment of Relapsed Multiple Myeloma

Data From Another Study Demonstrating the Efficacy of VELCADE Maintenance Monotherapy and Improvements in Quality of Life Presented at the 52nd American Society of Hematology Annual Meeting

BEERSE, Belgium, December 6, 2010 – Janssen Pharmaceutical Companies today announced the results from data
presented at the 52nd American Society for Hematology (ASH) Annual Meeting in
Orlando, which demonstrated … Read : VELCADE(R) (bortezomib) Administered Subcutaneously Shows Comparable Response Rates and Safety Profile Compared to Intravenous Administration in the Treatment of Relapsed Multiple Myeloma.

Torchmark Corporation Declares Dividend

MCKINNEY, Texas, December 6, 2010 – Torchmark Corporation (NYSE: TMK) announced that its Board of Directors
has declared a quarterly dividend of $.16 per share on all of the outstanding
common stock of the Company held of record as of the close of business of the
Company's transfer agent on January 6, 2011. The dividend will be … Original article on : Torchmark Corporation Declares Dividend.